DR6.F
ACADIA Pharmaceuticals Inc.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
25.01
▲ 0.35 (1.42%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.01
Prev close
24.66
Day high
25.01
Day low
25.01
Volume
100
Market cap
$4.31B
P/E (TTM)
13.09
52W range
17.52 – 25.79
Day trading desk
Gap from prior close
+1.42%
Prior close 24.66
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
25.01 – 25.01
Position in range
—
—
ATR (14D)
0.58
2.31% of price
Prior day high
24.66
PDH
Prior day low
24.66
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 1
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.35%
+4.6%
1M
+15.52%
+12.3%
3M
+37.80%
+35.5%
6M
+18.93%
+7.1%
YTD
+25.80%
+13.9%
1Y
+14.83%
-5.2%
3Y
+1.67%
-73.2%
5Y
+84.44%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DR6.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
566.88K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 6, 26 | SCHNEYER MARK C. Chief Financial Officer |
CONVERSION | 20.14K | $359.31K | Direct |
| Aug 6, 26 | SCHNEYER MARK C. Chief Financial Officer |
SELL | 20.14K | $587.24K | Direct |
| Jul 30, 26 | THOMPSON ELIZABETH H.Z. Officer |
SELL | 16.56K | $432.66K | Direct |
| Jul 29, 26 | THOMPSON ELIZABETH H.Z. Officer |
— | 32.27K | — | Direct |
| Jun 26, 26 | KIHARA JAMES Officer |
SELL | 11.42K | $297.91K | Direct |
| May 29, 26 | HARRIGAN EDMUND P. M.D. Director |
— | 8.11K | — | Direct |
| May 29, 26 | DALY JAMES M. Director |
— | 8.11K | — | Direct |
| May 29, 26 | POOLE JONATHAN Director |
— | 2.01K | — | Direct |
| May 29, 26 | BREGE LAURA A Director |
— | 8.11K | — | Direct |
| May 29, 26 | GAROFALO ELIZABETH AMY M.D. Director |
— | 8.11K | — | Direct |
| May 29, 26 | NDU ADORA Director |
— | 8.11K | — | Direct |
| May 29, 26 | BAKER BROS ADVISORS L.P. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 37.24K | $0 | Indirect |
| May 26, 26 | KIHARA JAMES Officer |
SELL | 5.40K | $114.39K | Direct |
| May 4, 26 | SCHNEYER MARK C. Chief Financial Officer |
SELL | 3.51K | $76.40K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
BAKER BROTHERS LIFE SCIENCES L P |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
BREGE LAURA A |
Director | 23.20K | Conversion of Exercise of derivative security |
GAROFALO ELIZABETH AMY M.D. |
Director | 33.49K | Conversion of Exercise of derivative security |
HARRIGAN EDMUND P. M.D. |
Director | 43.15K | Conversion of Exercise of derivative security |
NDU ADORA |
Director | 32.91K | Conversion of Exercise of derivative security |
SCHNEYER MARK C. |
Chief Financial Officer | 67.83K | Conversion of Exercise of derivative security |
SOLAND DANIEL B |
Director | 44.04K | Conversion of Exercise of derivative security |
TEEHAN BRENDAN |
Chief Operating Officer | 62.10K | Sale |
THOMPSON ELIZABETH H.Z. |
Officer | 18.99K | Sale |
Fundamentals
Market cap$4.31B
Enterprise value$3.37B
Revenue (TTM)$1.14B
Gross profit$706.66M
EBITDA$98.39M
Net income$380.48M
EPS (TTM)$1.91
Free cash flow$68.65M
Total cash$956.47M
Total debt$73.85M
Book value / share$6.50
Shares outstanding172.31M
Float128.35M
Short % of float—
Dividend yield—
Beta (5Y)0.85
Valuation & profitability ratios
Trailing P/E13.09
Forward P/E-27.18
PEG ratio51.02
Price / sales—
Price / book3.85
EV / revenue2.96
EV / EBITDA34.22
Gross margin62.06%
Operating margin12.29%
Profit margin33.42%
Return on equity35.74%
Return on assets3.64%
Debt / equity5.65
Current ratio3.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.07B | $957.80M | $726.44M | $517.24M | +11.9% |
| Operating revenue | $1.07B | $957.80M | $726.44M | $517.24M | +11.9% |
| Cost of revenue | $89.00M | $81.84M | $41.64M | $10.17M | +8.7% |
| Gross profit | $982.51M | $875.96M | $684.80M | $507.07M | +12.2% |
| Research & development | $328.80M | $303.25M | $351.62M | $361.57M | +8.4% |
| Selling, general & admin | $548.89M | $488.43M | $406.56M | $369.09M | +12.4% |
| Total operating expense | $877.70M | $791.68M | $758.18M | $730.66M | +10.9% |
| Operating income | $104.81M | $84.28M | -$73.38M | -$223.60M | +24.4% |
| Net interest income | $31.72M | $25.46M | $17.23M | $6.61M | +24.6% |
| Pre-tax income | $138.90M | $258.07M | -$51.04M | -$213.44M | -46.2% |
| Tax provision | -$252.10M | $31.62M | $10.25M | $2.53M | -897.2% |
| Net income | $391.00M | $226.45M | -$61.29M | -$215.97M | +72.7% |
| Net income to common | $391.00M | $226.45M | -$61.29M | -$215.97M | +72.7% |
| Basic EPS | 2.32 | 1.37 | -0.37 | -1.34 | +69.3% |
| Diluted EPS | 2.30 | 1.36 | -0.37 | -1.34 | +69.1% |
| EBIT | $104.81M | $84.28M | -$73.38M | -$223.60M | +24.4% |
| EBITDA | $116.57M | $100.16M | -$67.83M | -$221.57M | +16.4% |
| Basic shares | 168.36M | 165.72M | 163.82M | 161.68M | +1.6% |
| Diluted shares | 169.92M | 166.36M | 163.82M | 161.68M | +2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $177.69M | $319.59M | $188.66M | $114.85M | -44.4% |
| Cash & short-term investments | $819.69M | $755.99M | $438.87M | $416.82M | +8.4% |
| Accounts receivable | $121.46M | $98.74M | $98.27M | $62.20M | +23.0% |
| Inventory | $34.67M | $21.95M | $35.82M | $6.64M | +58.0% |
| Total current assets | $1.06B | $938.32M | $616.13M | $507.94M | +13.2% |
| Property, plant & equipment | $54.87M | $50.79M | $56.47M | $61.59M | +8.0% |
| Goodwill & intangibles | $108.89M | $119.78M | $65.49M | $0 | -9.1% |
| Total assets | $1.56B | $1.19B | $748.96M | $587.81M | +31.7% |
| Total current liabilities | $277.11M | $394.87M | $254.25M | $125.63M | -29.8% |
| Total debt | $52.19M | $51.99M | $57.20M | $62.00M | +0.4% |
| Total liabilities | $336.81M | $454.96M | $317.20M | $187.40M | -26.0% |
| Retained earnings | -$1.81B | -$2.20B | -$2.43B | -$2.37B | +17.7% |
| Shareholder equity | $1.23B | $732.79M | $431.75M | $400.41M | +67.5% |
| Working capital | $785.00M | $543.45M | $361.87M | $382.31M | +44.4% |
| Net tangible assets | $1.12B | $613.01M | $366.26M | $400.41M | +82.5% |
| Shares issued | 170.31M | 166.71M | 164.65M | 162.06M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $391.00M | $226.45M | -$61.29M | -$215.97M | — | +72.7% |
| Depreciation & amortisation | $11.76M | $15.88M | $5.55M | $2.03M | — | -26.0% |
| Stock-based compensation | $52.13M | $67.05M | $66.42M | $68.20M | — | -22.2% |
| Change in working capital | -$89.76M | $4.16M | $18.13M | $37.99M | — | -2,260.2% |
| Operating cash flow | $109.84M | $157.72M | $16.70M | -$114.03M | — | -30.4% |
| Capital expenditure | -$4.69M | -$523.00K | -$50.00K | — | -$1.12M | -796.7% |
| Investing cash flow | -$302.56M | -$30.54M | $32.00M | $73.24M | — | -890.8% |
| Financing cash flow | $49.88M | $6.84M | $25.13M | $8.20M | — | +628.8% |
| Free cash flow | $105.15M | $157.20M | $16.65M | -$114.03M | — | -33.1% |
| End cash position | $185.54M | $328.36M | $194.43M | $120.62M | — | -43.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $307.96M | $268.06M | $283.99M | $278.63M | $264.57M | — | +14.9% |
| Operating revenue | $307.96M | $268.06M | $283.99M | $278.63M | $264.57M | — | +14.9% |
| Cost of revenue | $28.32M | $24.79M | $26.23M | $21.65M | $20.73M | — | +14.2% |
| Gross profit | $279.64M | $243.27M | $257.76M | $256.99M | $243.83M | — | +15.0% |
| Research & development | $81.56M | $76.87M | $84.76M | $87.83M | $77.95M | — | +6.1% |
| Selling, general & admin | $160.25M | $171.02M | $155.62M | $133.40M | $133.51M | — | -6.3% |
| Total operating expense | $241.81M | $247.89M | $240.37M | $221.23M | $211.46M | — | -2.5% |
| Operating income | $37.84M | -$4.62M | $17.39M | $35.76M | $32.37M | — | +919.7% |
| Net interest income | $7.99M | $8.05M | $8.33M | $8.25M | $7.24M | — | -0.8% |
| Pre-tax income | $46.47M | $3.98M | $26.32M | $44.59M | $40.21M | — | +1,067.4% |
| Tax provision | $14.97M | $344.00K | -$247.25M | -$27.18M | $13.54M | — | +4,252.6% |
| Net income | $31.50M | $3.64M | $273.57M | $71.78M | $26.67M | — | +766.1% |
| Net income to common | $31.50M | $3.64M | $273.57M | $71.78M | $26.67M | — | +766.1% |
| Basic EPS | 0.18 | 0.02 | 1.62 | — | 0.16 | 0.11 | +800.0% |
| Diluted EPS | 0.18 | 0.02 | 1.60 | — | 0.16 | 0.11 | +800.0% |
| EBIT | $37.84M | -$4.62M | $17.39M | $35.76M | $32.37M | — | +919.7% |
| EBITDA | $40.99M | -$1.62M | $20.32M | $38.71M | $35.31M | — | +2,625.8% |
| Basic shares | 171.60M | 170.52M | 169.34M | — | 167.83M | 166.81M | +0.6% |
| Diluted shares | 172.85M | 172.71M | 171.36M | — | 168.68M | 167.67M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $384.99M | $282.21M | $177.69M | $258.00M | $253.64M | +36.4% |
| Cash & short-term investments | $956.47M | $851.46M | $819.69M | $847.02M | $762.00M | +12.3% |
| Accounts receivable | $150.64M | $135.35M | $121.46M | $115.85M | $107.50M | +11.3% |
| Inventory | $32.37M | $31.57M | $34.67M | $29.10M | $26.12M | +2.5% |
| Total current assets | $1.22B | $1.10B | $1.06B | $1.08B | $960.55M | +11.7% |
| Property, plant & equipment | $86.53M | $60.93M | $54.87M | $53.38M | $54.54M | +42.0% |
| Goodwill & intangibles | $103.45M | $106.17M | $108.89M | $111.61M | $114.34M | -2.6% |
| Total assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | +8.6% |
| Total current liabilities | $361.44M | $305.52M | $277.11M | $356.58M | $330.02M | +18.3% |
| Total debt | $73.85M | $50.79M | $52.19M | $54.81M | $56.29M | +45.4% |
| Total liabilities | $436.29M | $357.16M | $336.81M | $413.50M | $403.17M | +22.2% |
| Retained earnings | -$1.78B | -$1.81B | -$1.81B | -$2.09B | -$2.16B | +1.7% |
| Shareholder equity | $1.31B | $1.25B | $1.23B | $917.27M | $822.38M | +4.7% |
| Working capital | $863.11M | $790.49M | $785.00M | $719.84M | $630.53M | +9.2% |
| Net tangible assets | $1.20B | $1.14B | $1.12B | $805.66M | $708.04M | +5.4% |
| Shares issued | 172.13M | 171.09M | 170.31M | 169.15M | 168.61M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $31.50M | $3.64M | $273.57M | $71.78M | $26.67M | — | +766.1% |
| Depreciation & amortisation | $3.16M | $2.99M | $2.92M | $2.95M | $2.94M | — | +5.5% |
| Stock-based compensation | $16.94M | $14.70M | $13.23M | $13.18M | $14.34M | — | +15.3% |
| Change in working capital | $39.46M | $13.20M | -$87.91M | -$12.52M | $21.55M | — | +198.9% |
| Operating cash flow | $100.78M | $33.98M | -$48.73M | $74.29M | $63.96M | — | +196.6% |
| Capital expenditure | -$5.09M | -$5.21M | — | -$99.23M | -$297.00K | -$98.84M | +2.4% |
| Investing cash flow | -$8.53M | $66.28M | -$55.87M | -$79.35M | -$43.29M | — | -112.9% |
| Financing cash flow | $10.49M | $4.23M | $22.67M | $9.42M | $15.96M | — | +148.0% |
| Free cash flow | $95.69M | $28.77M | $46.10M | -$24.94M | $162.50M | — | +232.6% |
| End cash position | $392.83M | $290.06M | $185.54M | $267.47M | $263.11M | — | +35.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $331.79M | +19.1% |
| Next quarter | — | — | $362.69M | +27.7% |
| Current year | — | — | $1.27B | +18.8% |
| Next year | — | — | $1.43B | +12.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.33%
Held by institutions99.76%
Institutions holding479
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.05
-0.17% from price
SMA 20
24.19
+3.38% from price
SMA 50
22.46
+11.35% from price
SMA 100
20.48
+22.11% from price
SMA 200
20.06
+24.66% from price
EMA 12
24.75
+1.07% from price
EMA 26
23.91
+4.61% from price
EMA 50
22.74
+10.00% from price
RSI (14)
59.6
Neutral
MACD (12,26,9)
0.84
Hist -0.04
ATR (14)
0.58
2.31% of price
Realised vol 30D
36.7%
Annualised
Bollinger upper
26.57
20, 2σ
Bollinger lower
21.81
20, 2σ
50 / 200 cross
Golden
22.46 vs 20.06
Trend bias
Above 200
+24.66%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.01
Less volatile than market
Correlation to SPY
0.00
Largely independent
Realised vol 30D
36.7%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-23.1%
Peak to trough
Max drawdown 5Y
-57.6%
Peak to trough
ATR 14
0.58
2.31% of price
Beta (reported)
0.85
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Oppenheimer | MAINTAINED | Perform | Perform |
| Aug 5, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 21, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Jul 21, 26 | Stifel | MAINTAINED | Hold | Hold |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Jun 29, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jun 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Headlines
IHCL to merge Oriental Hotels under proposed share-swap deal
Hotel Management Network · 4m ago
Houlihan Lokey (HLI): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 5m ago
LIVE: US unveils new sanctions on Iran
Yahoo Finance Video · 6m ago
CPK chooses T-ROC Global to deploy automated food kiosks
Verdict Food Service · 7m ago
Dunkin’ and BARK Unleash First-Ever Doggie Drive-Thru
QSR · 9m ago
XPENG Reports Q2 2026 Results: Gross Margin Reaches 20.7%, Overseas Market Drives 25% of H1 Revenue
PR Newswire · 10m ago
Cut Flowers Market Size to Reach $52.78 Billion by 2031 as Online Ordering and Cold-Chain Innovation Reshape Global Trade, Reports Mordor Intelligence
PR Newswire · 11m ago
Visy launches automated labelling system for fresh produce packs
Packaging Gateway · 11m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.